125 related articles for article (PubMed ID: 21045137)
1. Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice.
Wang Y; James M; Wen W; Lu Y; Szabo E; Lubet RA; You M
Mol Cancer Ther; 2010 Nov; 9(11):3074-82. PubMed ID: 21045137
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice.
Fu H; Zhang J; Pan J; Zhang Q; Lu Y; Wen W; Lubet RA; Szabo E; Chen R; Wang Y; Chen DR; You M
Mol Carcinog; 2011 Dec; 50(12):913-21. PubMed ID: 21374736
[TBL] [Abstract][Full Text] [Related]
3. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice.
Wang Y; Zhang Z; Kastens E; Lubet RA; You M
Cancer Res; 2003 Aug; 63(15):4389-95. PubMed ID: 12907609
[TBL] [Abstract][Full Text] [Related]
4. The Second-Generation PGI2 Analogue Treprostinil Fails to Chemoprevent Tumors in a Murine Lung Adenocarcinoma Model.
Dwyer-Nield L; Hickey GA; Friedman M; Choo K; McArthur DG; Tennis MA; New ML; Geraci M; Keith RL
Cancer Prev Res (Phila); 2017 Nov; 10(11):671-679. PubMed ID: 28851689
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.
Karoor V; Le M; Merrick D; Dempsey EC; Miller YE
Cancer Prev Res (Phila); 2010 Sep; 3(9):1141-7. PubMed ID: 20647338
[TBL] [Abstract][Full Text] [Related]
6. Prevention of lung cancer progression by bexarotene in mouse models.
Wang Y; Zhang Z; Yao R; Jia D; Wang D; Lubet RA; You M
Oncogene; 2006 Mar; 25(9):1320-9. PubMed ID: 16247446
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis.
Suzuki S; Mori Y; Nagano A; Naiki-Ito A; Kato H; Nagayasu Y; Kobayashi M; Kuno T; Takahashi S
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27973395
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of combined administration of antibiotics and anti-inflammatory drugs on lung tumor development initiated by N-nitrosobis(2-hydroxypropyl)amine in rats.
Tsutsumi M; Kitada H; Shiraiwa K; Takahama M; Tsujiuchi T; Sakitani H; Sasaki Y; Murakawa K; Yoshimoto M; Konishi Y
Carcinogenesis; 2000 Feb; 21(2):251-6. PubMed ID: 10657965
[TBL] [Abstract][Full Text] [Related]
9. Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma.
Takeuchi Y; Takahashi M; Sakano K; Mutoh M; Niho N; Yamamoto M; Sato H; Sugimura T; Wakabayashi K
Carcinogenesis; 2007 Aug; 28(8):1692-6. PubMed ID: 17449904
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone prevents smoking carcinogen-induced lung tumor development in mice.
Li MY; Kong AW; Yuan H; Ma LT; Hsin MK; Wan IY; Underwood MJ; Chen GG
Curr Cancer Drug Targets; 2012 Jul; 12(6):597-606. PubMed ID: 22463586
[TBL] [Abstract][Full Text] [Related]
11. Chemoprevention of vinyl carbamate-induced lung tumors in strain A mice.
Gunning WT; Kramer PM; Lubet RA; Steele VE; Pereira MA
Exp Lung Res; 2000 Dec; 26(8):757-72. PubMed ID: 11195469
[TBL] [Abstract][Full Text] [Related]
12. PPARgamma agonism inhibits progression of premalignant lesions in a murine lung squamous cell carcinoma model.
Dwyer-Nield LD; McArthur DG; Hudish TM; Hudish LI; Mirita C; Sompel K; Smith AJ; Alavi K; Ghosh M; Merrick DT; Tennis MA; Keith RL
Int J Cancer; 2022 Dec; 151(12):2195-2205. PubMed ID: 35830207
[TBL] [Abstract][Full Text] [Related]
13. Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents.
Xiong D; Pan J; Zhang Q; Szabo E; Miller MS; Lubet RA; You M; Wang Y
Oncotarget; 2017 Mar; 8(12):18885-18900. PubMed ID: 27935865
[TBL] [Abstract][Full Text] [Related]
14. Suppressive effect of pioglitazone, a PPAR gamma ligand, on azoxymethane-induced colon aberrant crypt foci in KK-Ay mice.
Ueno T; Teraoka N; Takasu S; Nakano K; Takahashi M; Yamamoto M; Fujii G; Komiya M; Yanaka A; Wakabayashi K; Mutoh M
Asian Pac J Cancer Prev; 2012; 13(8):4067-73. PubMed ID: 23098518
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of ∆2-pioglitazone, an analogue of pioglitazone, on colon cancer cell survival: Evidence of drug treatment association with autophagy and activation of the Nrf2/Keap1 pathway.
Huber S; Valente S; Chaimbault P; Schohn H
Int J Oncol; 2014 Jul; 45(1):426-38. PubMed ID: 24788124
[TBL] [Abstract][Full Text] [Related]
16. Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention.
Seabloom DE; Galbraith AR; Haynes AM; Antonides JD; Wuertz BR; Miller WA; Miller KA; Steele VE; Miller MS; Clapper ML; O'Sullivan MG; Ondrey FG
Cancer Prev Res (Phila); 2017 Feb; 10(2):116-123. PubMed ID: 28052934
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone, an anti-diabetic drug requires sustained MAPK activation for its anti-tumor activity in MCF7 breast cancer cells, independent of PPAR-γ pathway.
Kole L; Sarkar M; Deb A; Giri B
Pharmacol Rep; 2016 Feb; 68(1):144-54. PubMed ID: 26721366
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment.
Grommes C; Landreth GE; Sastre M; Beck M; Feinstein DL; Jacobs AH; Schlegel U; Heneka MT
Mol Pharmacol; 2006 Nov; 70(5):1524-33. PubMed ID: 16887936
[TBL] [Abstract][Full Text] [Related]
19. Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer.
Yan Y; Lu Y; Wang M; Vikis H; Yao R; Wang Y; Lubet RA; You M
Mol Cancer Res; 2006 Dec; 4(12):971-81. PubMed ID: 17189387
[TBL] [Abstract][Full Text] [Related]
20. Prevention of mouse lung tumors by budesonide and its modulation of biomarkers.
Pereira MA; Li Y; Gunning WT; Kramer PM; Al-Yaqoub F; Lubet RA; Steele VE; Szabo E; Tao L
Carcinogenesis; 2002 Jul; 23(7):1185-92. PubMed ID: 12117777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
